HR and breast carcinoma: A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Assessing the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Hormone Receptor-Positive HER2-Negative Inoperable Locally Advanced or Metastatic Breast Cancer (MORPHEUS-HR+ Breast Cancer).